AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31302075 — intervention group
Group type: COMPARATOR
Intervention: RFA
Number of subjects: 55
Study 30450368 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training (MIAT) for 12 weeks, 50 min, 3 days per week, at 60% of maximal HR
Number of subjects: 24
Study 27664548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT) with 12 sessions, two involving family members
Number of subjects: 98
Study 27664548 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 98
Study 26025792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 ointment for 2 days
Number of subjects: 42
Study 26025792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study 23374199 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain treatment
Number of subjects: 61
Study 23374199 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 61
Study 23374199 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain treatment after full osteopathic treatment
Number of subjects: 61
Study 23374199 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment after full osteopathic treatment
Number of subjects: 61
Study 21675956 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors
Number of subjects: 43
Study 21675956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18481716 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiaji point group
Number of subjects: 90
Study 18481716 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing kidney and strengthening spleen point group
Number of subjects: 90
Study 18481716 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 90
Study 17134351 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Assistance System (DMAS) with adherence educational session
Number of subjects: 62
Study 17134351 — intervention group
Group type: COMPARATOR
Intervention: Control group (education only)
Number of subjects: 62
Study 12690586 — intervention group
Group type: EXPERIMENTAL
Intervention: Software search method (All About Outcomes)
Number of subjects: 30
Study 12690586 — intervention group
Group type: COMPARATOR
Intervention: Library search method
Number of subjects: 30
Study 10748808 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and plaster immobilisation
Number of subjects: 90
Study 10748808 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 90
Study 10748808 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 90
Study 9186253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (3,000 mg daily for 4 weeks)
Number of subjects: 13
Study 8098295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fortified procaine penicillin (PPF)
Number of subjects: 737
Study 8098295 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin
Number of subjects: 737
Study 8098295 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Control group)
Number of subjects: 737
Study 3329110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg daily)
Number of subjects: 108
Study 3329110 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg daily)
Number of subjects: 108
Study 3329110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam and Piroxicam
Number of subjects: 108
Study 29685693 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily for 15 days
Number of subjects: 40
Study 29685693 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 40
Study 27130369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant
Number of subjects: 20
Study 27130369 — intervention group
Group type: COMPARATOR
Intervention: VEGF-neutralizing protein
Number of subjects: 20
Study 24059271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with 60% oxygen preconditioning for 2 hours at 48, 24, and 6 hours before Cisplatin administration
Number of subjects: 80
Study 24059271 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin only (control group)
Number of subjects: 80
Study 22453707 — intervention group
Group type: EXPERIMENTAL
Intervention: Link Samahan® (one sachet daily in hot water)
Number of subjects: 956
Study 22453707 — intervention group
Group type: COMPARATOR
Intervention: Plain tea (control group)
Number of subjects: 956
Study 20576800 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to movie clips portraying smoking as helping to relax
Number of subjects: 77
Study 20576800 — intervention group
Group type: COMPARATOR
Intervention: Exposure to movie clips with no clear motive for smoking
Number of subjects: 77
Study 20576800 — intervention group
Group type: COMPARATOR
Intervention: Exposure to social smoking clips
Number of subjects: 77
Study 20576800 — intervention group
Group type: COMPARATOR
Intervention: Exposure to rebellious smoking clips
Number of subjects: 77
Study 18426595 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw)
Number of subjects: 553
Study 18426595 — intervention group
Group type: COMPARATOR
Intervention: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw)
Number of subjects: 553
Study 18426595 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a, 44 mcg sc tiw
Number of subjects: 553
Study 18426595 — intervention group
Group type: COMPARATOR
Intervention: IFN beta‐1a, 30 mcg im qw
Number of subjects: 553
Study 15937989 — intervention group
Group type: EXPERIMENTAL
Intervention: AU dollars 2 scratch lottery ticket
Number of subjects: 443
Study 15937989 — intervention group
Group type: COMPARATOR
Intervention: No incentive (control group)
Number of subjects: 443
Study 15937989 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder mailing
Number of subjects: 443
Study 12973881 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer generated consumer product information
Number of subjects: 179
Study 12973881 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer generated medication timetable
Number of subjects: 179
Study 12973881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 179
Study 12973881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study 11037895 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 100 mg/day (50 mg twice daily)
Number of subjects: 484
Study 11037895 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg/day and 150 mg/day
Number of subjects: 484
Study 11037895 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein (all dosages)
Number of subjects: 484
Study 11037895 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 150 mg/day
Number of subjects: 484
Study 11037895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 8803379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVL) 2 mg/kg
Number of subjects: 9
Study 8803379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVL) 5 mg/kg
Number of subjects: 9
Study 8803379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine
Number of subjects: 9
Study 1730902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated anti-HIV antibody-rich plasma (7 transfusions every 2 weeks)
Number of subjects: 18
Study 1730902 — intervention group
Group type: COMPARATOR
Intervention: Seronegative fresh-frozen plasma
Number of subjects: 18
Study 1730902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated anti-HIV antibody-rich plasma
Number of subjects: 18
Study 3901217 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (dosages varied: 250 mg four times a day; 500 mg three or four times a day; 1 g three or four times a day)
Number of subjects: 1723
Study 3901217 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 1723
Study 29879593 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel debridement of plantar hyperkeratoses
Number of subjects: 98
Study 29879593 — intervention group
Group type: COMPARATOR
Intervention: Simulated debridement (Control)
Number of subjects: 98
Study 26782858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 101
Study 26782858 — intervention group
Group type: COMPARATOR
Intervention: Balance and Toning (BAT)
Number of subjects: 101
Study 24873162 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical single-site single-port laparoscopic varicolectomy
Number of subjects: 80
Study 24873162 — intervention group
Group type: COMPARATOR
Intervention: Transumbilical single-site double-port laparoscopic varicolectomy
Number of subjects: 80
Study 24176458 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodocumentation (PD) plus standard of care
Number of subjects: 468
Study 24176458 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care without PD)
Number of subjects: 468
Study 24176458 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodocumentation (PD)
Number of subjects: 468
Study 20395338 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-DTPA
Number of subjects: 63
Study 20395338 — intervention group
Group type: EXPERIMENTAL
Intervention: Technegas
Number of subjects: 63
Study 18495737 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of albendazole daily for 8 days
Number of subjects: 178
Study 18495737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 15888509 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 0
Study 12560439 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage three-dimensional conformal radiotherapy (3D‐CRT) alone
Number of subjects: 115
Study 12560439 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage three-dimensional conformal radiotherapy (3D‐CRT) with neoadjuvant androgen deprivation
Number of subjects: 115
Study 10836329 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 microg x day(-1)
Number of subjects: 23
Study 10836329 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 microg x day(-1)
Number of subjects: 23
Study 10836329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BDP and FP
Number of subjects: 23
Study 8610836 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy
Number of subjects: 118
Study 8610836 — intervention group
Group type: COMPARATOR
Intervention: Usual community services (Control)
Number of subjects: 118
Study 1750591 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine titration using the Hemochron system
Number of subjects: 40
Study 1750591 — intervention group
Group type: COMPARATOR
Intervention: Empirical dose protocol
Number of subjects: 40
Study 7024767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortiron (R)‐Depot (11‐Desoxycorticosteronönanthat)
Number of subjects: 30
Study 7024767 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 30
Study 31960580 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing arm
Number of subjects: 2665
Study 31960580 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2665
Study 31960580 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing programme overall
Number of subjects: 2665
Study 30676300 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation
Number of subjects: 40
Study 30676300 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 40
Study 30676300 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for brachytherapy
Number of subjects: 40
Study 29199654 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and concurrent cisplatin infusion (Group B)
Number of subjects: 50
Study 29199654 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Group A)
Number of subjects: 50
Study 29199654 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy
Number of subjects: 50
Study 25661296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute
Number of subjects: 254
Study 25661296 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute
Number of subjects: 254
Study 25661296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute for proximal ureteral stones
Number of subjects: 254
Study 25661296 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute for proximal ureteral stones
Number of subjects: 254
Study 25661296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute for mid ureteral stones
Number of subjects: 254
Study 25661296 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute for mid ureteral stones
Number of subjects: 254
Study 25661296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute for distal ureteral stones
Number of subjects: 254
Study 25661296 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute for distal ureteral stones
Number of subjects: 254
Study 24382482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Number of subjects: 601
Study 24382482 — intervention group
Group type: COMPARATOR
Intervention: MCP1 rs1024611 polymorphic variants
Number of subjects: 601
Study 22991979 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI) including single-pill amlodipine/atorvastatin (SPAA)
Number of subjects: 0
Study 22991979 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 22991979 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI)
Number of subjects: 0
Study 19773619 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement augmentation (Group 1, n=12)
Number of subjects: 24
Study 19773619 — intervention group
Group type: COMPARATOR
Intervention: No bone cement augmentation (Group 2, n=12)
Number of subjects: 24
Study 18089874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 intravenously on day 1 with raltitrexed 3 mg/m2
Number of subjects: 250
Study 18089874 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 intravenously on day 1 without raltitrexed
Number of subjects: 250
Study 15336467 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin (15 mg/d, adjusted in 5 mg/d increments)
Number of subjects: 125
Study 15336467 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin (TID)
Number of subjects: 125
Study 11876710 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg/day for 2 weeks
Number of subjects: 124
Study 11876710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg/day for 2 weeks
Number of subjects: 124
Study 11876710 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole, 40 mg/day for 2 weeks
Number of subjects: 124
Study 11876710 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-drug withdrawal
Number of subjects: 124
Study 9632571 — intervention group
Group type: EXPERIMENTAL
Intervention: DeALPS-CT-2
Number of subjects: 75
Study 9632571 — intervention group
Group type: EXPERIMENTAL
Intervention: DeALPS-CT-1
Number of subjects: 75
Study 9632571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular vaccine
Number of subjects: 75
Study 9632571 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugates and cellular vaccine
Number of subjects: 75
Study 9632571 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugates
Number of subjects: 75
Study 9632571 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent sera from cholera patients
Number of subjects: 75
Study 8075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of objects for addition
Number of subjects: 55
Study 8075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of counting for addition
Number of subjects: 55
Study 8075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental calculations using knowledge of number facts and place value
Number of subjects: 55
Study 2766908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cisapride
Number of subjects: 18
Study 2766908 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 18
Study 2766908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16735 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (Halcion) 0.25 mg
Number of subjects: 45
Study 16735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31894029 — intervention group
Group type: EXPERIMENTAL
Intervention: NAD+ ADP‐ribosyl transferase 1 (NART) agonist (DAG‐structured PKC blockers (GF109203X))
Number of subjects: 120
Study 31894029 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (DNP) 10mg daily
Number of subjects: 120
Study 28489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) ¼ dilution (1.25 mg/dL)
Number of subjects: 83
Study 28489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) ¼ dilution
Number of subjects: 83
Study 28489468 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 83
Study 28489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) ½ dilution
Number of subjects: 83
Study 28489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) ½ dilution
Number of subjects: 83
Study 28489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) groups
Number of subjects: 83
Study 28489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) groups
Number of subjects: 83
Study 26176973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen (5 mg/325 mg)
Number of subjects: 240
Study 26176973 — intervention group
Group type: COMPARATOR
Intervention: Codeine/Acetaminophen (30 mg/300 mg)
Number of subjects: 240
Study 23953101 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL)
Number of subjects: 24
Study 21787184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (MTL) 20% (4 mL/kg)
Number of subjects: 47
Study 21787184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) 7.5% (2 mL/kg)
Number of subjects: 47
Study 21787184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 19336262 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose propofol
Number of subjects: 0
Study 19336262 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane preconditioning
Number of subjects: 0
Study 17592080 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g/d)
Number of subjects: 133
Study 17592080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 15106410 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprasol (40 mg/day) and de‐nol (480 mg/day)
Number of subjects: 63
Study 15106410 — intervention group
Group type: COMPARATOR
Intervention: omeprasol (40 mg/day)
Number of subjects: 63
Study 12492641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional recommendations based on evidence from RCT and other studies
Number of subjects: 0
Study 12492641 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental studies and descriptive epidemiological approaches
Number of subjects: 0
Study 9613647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered immunoglobulin (mainly immunoglobulin A), nasal spray, twice daily for 8 weeks
Number of subjects: 40
Study 9613647 — intervention group
Group type: COMPARATOR
Intervention: Placebo, nasal spray, twice daily for 8 weeks
Number of subjects: 40
Study 7972192 — intervention group
Group type: EXPERIMENTAL
Intervention: Wool and crepe bandages
Number of subjects: 0
Study 7972192 — intervention group
Group type: COMPARATOR
Intervention: Elasticated tubular bandage
Number of subjects: 0
Study 2493372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-piece breathing valve assembly
Number of subjects: 10
Study 2493372 — intervention group
Group type: COMPARATOR
Intervention: No breathing apparatus
Number of subjects: 10
Study 29130749 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (n=31)
Number of subjects: 60
Study 29130749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 60
Study 26473751 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 100 mg/day
Number of subjects: 358
Study 26473751 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 150 mg/day
Number of subjects: 358
Study 26473751 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 200 mg/day
Number of subjects: 358
Study 26473751 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 100 mg twice daily
Number of subjects: 358
Study 26473751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 24196971 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS and local injection of cobalamin
Number of subjects: 90
Study 24196971 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS with a combination of cobalamin and lidocaine
Number of subjects: 90
Study 24196971 — intervention group
Group type: COMPARATOR
Intervention: TENS and local injection of lidocaine
Number of subjects: 90
Study 23896920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer (IP)
Number of subjects: 564
Study 23896920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intercessory prayer)
Number of subjects: 564
Study 19838638 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 2
Study 19838638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Number of subjects: 2
Study 19838638 — intervention group
Group type: COMPARATOR
Intervention: L-alanine
Number of subjects: 2